Administration of 4-(<i>α</i>-L-Rhamnosyloxy)-benzyl Isothiocyanate Delays Disease Phenotype in SOD1<sup>G93A</sup> Rats: A Transgenic Model of Amyotrophic Lateral Sclerosis

<div>Chemical structures and production of GMG-ITC. Myr-catalyzed hydrolysis of 4-(<i>α</i>-L-rhamnosyloxy)-benzyl glucosinolate (glucomoringin, GMG) to produce 4-(<i>α</i>-L-rhamnosyloxy)-benzyl isothiocyanate (GMG-ITC).</div>

BioMed Research International

fig1

Figure 1

Figure 1: Administration of 4-(<i>α</i>-L-Rhamnosyloxy)-benzyl Isothiocyanate Delays Disease Phenotype in SOD1<sup>G93A</sup> Rats: A Transgenic Model of Amyotrophic Lateral Sclerosis 

Figure 1 | Administration of 4-(α-L-Rhamnosyloxy)-benzyl Isothiocyanate Delays Disease Phenotype in SOD1G93A Rats: A Transgenic Model of Amyotrophic Lateral Sclerosis 